Tumor SQSTM1 (p62) expression and T cells in colorectal cancer

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Kosumi, Keisuke ^a   Masugi, Yohei ^a   Yang, Juhong ^b   Qian, Zhi Rong ^a   Kim, Sun A ^c   Li, Wanwan ^a   Shi, Yan ^a   da Silva, Annacarolina ^a   Hamada, Tsuyoshi ^a   Liu, Li ^a,d   Gu, Mancang ^a   Twombly, Tyler S ^a   Cao, Yin ^d,e   Barbie, David A ^a   Nosho, Katsuhiko ^f   Baba, Hideo ^g   Garrett, Wendy S ^a,d   Meyerhardt, Jeffery A ^a   Giovannucci, Edward L ^d,h   Chan, Andrew T ^e,h,i   Fuchs, Charles S ^a,h   Ogino, Shuji ^a,d,h   Nishihara, Reiko ^a,d,h   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Adenocarcinoma; colorectum; immunoprevention; immunotherapy; molecular pathology

Indexed keywords

B RAF KINASE; CD45RO ANTIGEN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SEQUESTOSOME 1; TRANSCRIPTION FACTOR FOXP3;

AGED; ARTICLE; AUTOPHAGY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; ONCOGENE K RAS; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 85016565128     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1284720     Document Type: Article

References (76)

1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56-61; PMID:25838373; http://dx.doi.org/10.1126/science.aaa8172
2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
3. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
4. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade:a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
5. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33:1974-82; PMID:25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
6. Kaur J, Debnath J. Autophagy at the crossroads of catabolism and anabolism. Nat Rev Mol Cell Biol 2015; 16:461-72; PMID:26177004; http://dx.doi.org/10.1038/nrm4024
7. Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A, et al. p62, Upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 2016; 29:935-48; PMID:27211490; http://dx.doi.org/10.1016/j.ccell.2016.04.006
8. Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008; 68:6889-95; PMID:18757401; http://dx.doi.org/10.1158/0008-5472.CAN-08-0161
9. Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, Fox BA, Urba WJ, Hu HM. Tumor-derived autophagosome vaccine:mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 2011; 17:7047-57; PMID:22068657; http://dx.doi.org/10.1158/1078-0432.CCR-11-0951
10. Li Y, Hahn T, Garrison K, Cui ZH, Thorburn A, Thorburn J, Hu HM, Akporiaye ET. The vitamin E analogue alpha-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Res 2012; 72:3535-45; PMID:22745370; http://dx.doi.org/10.1158/0008-5472.CAN-11-3103
11. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity 2013; 39:211-27; PMID:23973220; http://dx.doi.org/10.1016/j.immuni.2013.07.017
12. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282-6; PMID:19741708; http://dx.doi.org/10.1038/nature08296
13. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
14. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, et al. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 2012; 8:413-5; PMID:22361584; http://dx.doi.org/10.4161/auto.19009
15. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013; 13:722-37; PMID:24064518; http://dx.doi.org/10.1038/nri3532
16. Pan H, Chen L, Xu Y, Han W, Lou F, Fei W, Liu S, Jing Z, Sui X. Autophagy-associated immune responses and cancer immunotherapy. Oncotarget 2016; 7(16):21235-46; PMID:26788909; http://dx.doi.org/10.18632/oncotarget.6908
17. Zhong Z, Sanchez-Lopez E, Karin M. Autophagy, inflammation, and immunity:a Troika governing cancer and its treatment. Cell 2016; 166:288-98; PMID:27419869; http://dx.doi.org/10.1016/j.cell.2016.05.051
18. Pietrocola F, Pol J, Vacchelli E, Baracco EE, Levesque S, Castoldi F, Maiuri MC, Madeo F, Kroemer G. Autophagy induction for the treatment of cancer. Autophagy 2016; 12(10):1962-1964; PMID:27532519; http://dx.doi.org/10.1080/15548627.2016.1214778
19. Cui J, Jin S, Wang RF. The BECN1-USP19 axis plays a role in the crosstalk between autophagy and antiviral immune responses. Autophagy 2016; 12(7):1-2; PMID:27096686; http://dx.doi.org/10.1080/15548627.2016.1173801
20. Ladoire S, Enot D, Senovilla L, Chaix M, Zitvogel L, Kroemer G. Positive impact of autophagy in human breast cancer cells on local immunosurveillance. Oncoimmunology 2016; 5:e1174801; PMID:27471653; http://dx.doi.org/10.1080/2162402X.2016.1174801
21. Ladoire S, Enot D, Senovilla L, Ghiringhelli F, Poirier-Colame V, Chaba K, Semeraro M, Chaix M, Penault-Llorca F, Arnould L, et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy 2016; 12:864-75; PMID:26979828; http://dx.doi.org/10.1080/15548627.2016.1154244
22. Ladoire S, Senovilla L, Enot D, Ghiringhelli F, Poirier-Colame V, Chaba K, Erdag G, Schaefer JT, Deacon DH, Zitvogel L, et al. Biomarkers of immunogenic stress in metastases from melanoma patients:correlations with the immune infiltrate. Oncoimmunology 2016; 5:e1160193; PMID:27471635; http://dx.doi.org/10.1080/2162402X.2016.1160193
23. Bjorkoy G, Lamark T, Pankiv S, Overvatn A, Brech A, Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol 2009; 452:181-97. PMID:19200883; http://dx.doi.org/10.1016/S0076-6879(08)03612-4
24. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009; 137:1062-75; PMID:19524509; http://dx.doi.org/10.1016/j.cell.2009.03.048
25. Rogov V, Dotsch V, Johansen T, Kirkin V. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell 2014; 53:167-78; PMID:24462201; http://dx.doi.org/10.1016/j.molcel.2013.12.014
26. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H, Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005; 171:603-14; PMID:16286508; http://dx.doi.org/10.1083/jcb.200507002
27. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 2007; 282:24131-45; PMID:17580304; http://dx.doi.org/10.1074/jbc.M702824200
28. Katsuragi Y, Ichimura Y, Komatsu M. p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J 2015; 282:4672-8; PMID:26432171; http://dx.doi.org/10.1111/febs.13540
29. Taniguchi K, Yamachika S, He F, Karin M. p62/SQSTM1—Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer. FEBS Lett 2016; 590(15):2375-97; PMID:27404485; http://dx.doi.org/10.1002/1873-3468.12301
30. Kanayama M, Inoue M, Danzaki K, Hammer G, He YW, Shinohara ML. Autophagy enhances NFkappaB activity in specific tissue macrophages by sequestering A20 to boost antifungal immunity. Nat Commun 2015; 6:5779; PMID:25609235; http://dx.doi.org/10.1038/ncomms6779
31. Lee Y, Sasai M, Ma JS, Sakaguchi N, Ohshima J, Bando H, Saitoh T, Akira S, Yamamoto M. p62 plays a specific role in interferon-gamma-induced presentation of a toxoplasma vacuolar antigen. Cell Rep 2015; 13:223-33; PMID:26440898; http://dx.doi.org/10.1016/j.celrep.2015.09.005
32. Andersen AN, Landsverk OJ, Simonsen A, Bogen B, Corthay A, Oynebraten I. Coupling of HIV-1 antigen to the selective autophagy receptor SQSTM1/p62 promotes T-cell-mediated immunity. Front Immunol 2016; 7:167; PMID:27242780; http://dx.doi.org/10.3389/fimmu.2016.00167
33. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T. Colorectal cancer. Nat Rev Dis Primers 2015; 1:15065; PMID:27189416; http://dx.doi.org/10.1038/nrdp.2015.65
34. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer:emerging biomarkers. Gastroenterology 2015; 149:1204-25.e12; PMID:26216839; http://dx.doi.org/10.1053/j.gastro.2015.07.011
35. Di Caro G, Marchesi F, Laghi L, Grizzi F. Immune cells:plastic players along colorectal cancer progression. J Cell Mol Med 2013; 17:1088-95; PMID:24151976; http://dx.doi.org/10.1111/jcmm.12117
36. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer:implications for disease behavior and prevention. Int J Mol Sci 2013; 14:16365-85; PMID:23965959; http://dx.doi.org/10.3390/ijms140816365
37. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 2016; 44:698-711; PMID:26982367; http://dx.doi.org/10.1016/j.immuni.2016.02.025
38. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
39. Shang B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers:a systematic review and meta-analysis. Sci Rep 2015; 5:15179; PMID:26462617; http://dx.doi.org/10.1038/srep15179
40. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L, Li C. Tumour-infiltrating inflammation and prognosis in colorectal cancer:systematic review and meta-analysis. Br J Cancer 2014; 110:1595-605; PMID:24504370; http://dx.doi.org/10.1038/bjc.2014.46
41. Palmqvist R, Wikberg M, Ling A, Edin S. The association of immune cell infiltration and prognosis in colorectal cancer. Curr Colorectal Cancer Rep 2013; 9:372-9;; http://dx.doi.org/10.1007/s11888-013-0192-3
42. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology–analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8:711-9; PMID:21826083; http://dx.doi.org/10.1038/nrclinonc.2011.122
43. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis:cohort study and literature review. J Pathol 2010; 222:350-66; PMID:20927778; http://dx.doi.org/10.1002/path.2774
44. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009; 15:6412-20; PMID:19825961; http://dx.doi.org/10.1158/1078-0432.CCR-09-1438
45. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5:43-51; PMID:25358689; http://dx.doi.org/10.1158/2159-8290.CD-14-0863
46. Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther 2013; 14:100-7; PMID:23192274; http://dx.doi.org/10.4161/cbt.22954
47. Ren F, Shu G, Liu G, Liu D, Zhou J, Yuan L, Zhou J. Knockdown of p62/sequestosome 1 attenuates autophagy and inhibits colorectal cancer cell growth. Mol Cell Biochem 2014; 385:95-102; PMID:24065390; http://dx.doi.org/10.1007/s11010-013-1818-0
48. Kocarnik JM, Shiovitz S, Phipps AI. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 2015; 3:269-76. PMID:26337942; http://dx.doi.org/10.1093/gastro/gov046
49. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012; 12:621-8; PMID:22845482; http://dx.doi.org/10.1586/erm.12.46
50. Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer:molecular features of adipose tissue. J Transl Med 2016; 14:21; PMID:26801617; http://dx.doi.org/10.1186/s12967-016-0772-5
51. Roy HK, Turzhitsky V, Wali R, Radosevich AJ, Jovanovic B, Della'Zanna G, Umar A, Rubin DT, Goldberg MJ, Bianchi L, et al. Spectral biomarkers for chemoprevention of colonic neoplasia:a placebo-controlled double-blinded trial with aspirin. Gut 2017; 66:285-92; PMID:26503631; http://dx.doi.org/10.1136/gutjnl-2015-309996
52. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer 2017; 17(2):79-92; PMID:28050011; http://dx.doi.org/10.1038/nrc.2016.126
53. Rescigno T, Micolucci L, Tecce MF, Capasso A. Bioactive nutrients and nutrigenomics in age-related diseases. Molecules 2017; 22:105; PMID:28075340; http://dx.doi.org/10.3390/molecules22010105
54. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi.org/10.1002/path.4287
55. Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med 2014; 6:228ra37; PMID:24648340; http://dx.doi.org/10.1126/scitranslmed.3007240
56. Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol 2014; 14:154-65; PMID:24481337; http://dx.doi.org/10.1038/nri3605
57. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 2016; 22(6):679-84; PMID:27111280; http://dx.doi.org/10.1038/nm.4086
58. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas:the paradox of colorectal cancer. Cancer Immunol Immunother 2011; 60:909-18; PMID:21644034; http://dx.doi.org/10.1007/s00262-011-1046-y
59. English L, Chemali M, Duron J, Rondeau C, Laplante A, Gingras D, Alexander D, Leib D, Norbury C, Lippé R, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 2009; 10:480-7; PMID:19305394; http://dx.doi.org/10.1038/ni.1720
60. Tsai WT, Lo YC, Wu MS, Li CY, Kuo YP, Lai YH, Tsai Y, Chen KC, Chuang TH, Yao CH, et al. Mycotoxin patulin suppresses innate immune responses by mitochondrial dysfunction and p62/sequestosome-1-dependent mitophagy. J Biol Chem 2016; 291(37):19299-311; PMID:27458013; http://dx.doi.org/10.1074/jbc.M115.686683
61. Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A. BRAF associated autophagy exploitation:BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. Oncotarget 2016; 7:9188-221. PMID:26802026; http://dx.doi.org/10.18632/oncotarget.6942
62. Tang B, Wang K, Jia YP, Zhu P, Fang Y, Zhang ZJ, Mao XH, Li Q, Zeng DZ. Fusobacterium nucleatum-induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 cells. PLoS One 2016; 11:e0165701; PMID:27828984; http://dx.doi.org/10.1371/journal.pone.0165701
63. Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P, Qian ZR, Zhang X, Wu K, Nan H, et al. Review article:The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 2016; 27:602-11; PMID:26928707; http://dx.doi.org/10.1097/EDE.0000000000000471
64. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA 2013; 309:2563-71; PMID:23800934; http://dx.doi.org/10.1001/jama.2013.6599
65. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369:1095-105; PMID:24047059; http://dx.doi.org/10.1056/NEJMoa1301969
66. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367:1596-606; PMID:23094721; http://dx.doi.org/10.1056/NEJMoa1207756
67. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Colorectal cancer:a tale of two sides or a continuum? Gut 2012; 61:794-7; PMID:22490520; http://dx.doi.org/10.1136/gutjnl-2012-302014
68. Cao Y, Nishihara R, Qian ZR, Song M, Mima K, Inamura K, et al. Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology 2016; 151:879-92 e4; PMID:27475305; http://dx.doi.org/10.1053/j.gastro.2016.07.030
69. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356:2131-42; PMID:17522398; http://dx.doi.org/10.1056/NEJMoa067208
70. Lamb CA, Yoshimori T, Tooze SA. The autophagosome:origins unknown, biogenesis complex. Nat Rev Mol Cell Biol 2013; 14:759-74; PMID:24201109; http://dx.doi.org/10.1038/nrm3696
71. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58:90-6; PMID:18832519; http://dx.doi.org/10.1136/gut.2008.155473
72. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008; 3:e3698; PMID:19002263; http://dx.doi.org/10.1371/journal.pone.0003698
73. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer:cohort study and literature review. Mol Cancer 2014; 13:135; PMID:24885062; http://dx.doi.org/10.1186/1476-4598-13-135
74. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, et al. Prognostic role of PIK3CA mutation in colorectal cancer:cohort study and literature review. Clin Cancer Res 2012; 18:2257-68; PMID:22357840; http://dx.doi.org/10.1158/1078-0432.CCR-11-2410
75. Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 2015; 1:653-61; PMID:26181352; http://dx.doi.org/10.1001/jamaoncol.2015.1377
76. Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016; 65:1973-80; PMID:26311717; http://dx.doi.org/10.1136/gutjnl-2015-310101